首页> 外文期刊>Journal of neuro-oncology. >Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.
【24h】

Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors.

机译:用同种异体分泌白介素2的成纤维细胞进行治疗可预防恶性脑瘤的发展。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have reported that mice with an intracerebral (i.c.) malignant glioma or breast cancer treated with i.c. injection of allogeneic fibroblasts genetically engineered to secrete interleukin-2 (IL-2) survived longer than mice in various control groups. The goal of the present study was to determine the effectiveness of utilizing IL-2 secreting allogeneic fibroblasts as a protective treatment to prevent the development of an i.c. glioma or breast carcinoma. Using an intracranial microcannula system that we developed, the animals received weekly injections of the cellular vaccine prior to the introduction of tumor cells via the cannula. The results demonstrate a significant delay (P < 0.005) in the development of glioma in the animals pre-treated with either allogeneic non-secreting or IL-2-secreting fibroblasts prior to introduction of tumor cells. In addition, 50% of the animals pre-treated with IL-2 secreting allogeneic fibroblasts injected subsequently with G1261 glioma cells did not develop a tumor, while all of the animals injected with glioma cells alone and 92% of those treated with non-secreting fibroblasts eventually died. The long-term survivors from the pre-treatment group were subsequently re-challenged with tumor and compared to naive controls. There was evidence that long-term immunity was established in the pre-treated animals, since there was a significant prolongation of survival (P < 0.01). In similar experiments using breast cancer cells, 62% of the animals pre-treated with non-secreting allogeneic fibroblasts and 75% of the animals pre-treated with allogeneic IL-2 secreting fibroblasts subsequently injected with SB-5b breast carcinoma cells did not develop tumors and had a significant prolongation of survival. These data suggest that i.c. injection of allogeneic IL-2 secreting fibroblasts are effective as a protective treatment in the prevention of the development of a brain tumor when the fibroblasts are introduced into the same site where the tumor is subsequently injected.
机译:我们已经报道过,患有脑内(i.c.)恶性神经胶质瘤或经i.c.治疗的乳腺癌的小鼠。经过基因工程改造以分泌白介素2(IL-2)的同种异体成纤维细胞注射比各对照组小鼠存活时间更长。本研究的目的是确定利用分泌IL-2的同种异体成纤维细胞作为预防性治疗的预防方法。神经胶质瘤或乳腺癌。使用我们开发的颅内微插管系统,这些动物每周接受一次细胞疫苗注射,然后再通过插管引入肿瘤细胞。结果表明,在引入肿瘤细胞之前,用同种异体非分泌性成纤维细胞或IL-2分泌性成纤维细胞预处理的动物中神经胶质瘤的发展显着延迟(P <0.005)。此外,用IL126分泌的同种异体成纤维细胞预处理并随后注射G1261胶质瘤细胞的动物中,有50%没有发展为肿瘤,而所有单独注射胶质瘤细胞的动物和92%用非分泌物治疗的动物成纤维细胞最终死亡。随后将来自预处理组的长期幸存者再次挑战为肿瘤,并与单纯对照组进行了比较。有证据表明,由于显着延长了生存期,因此在预处理的动物中建立了长期免疫(P <0.01)。在使用乳腺癌细胞的类似实验中,未注射异源成纤维细胞预处理的动物中有62%以及随后注射SB-5b乳腺癌细胞的经异源IL-2分泌纤维细胞预处理过的动物中没有75%肿瘤并有明显的生存期延长。这些数据表明,当将成纤维细胞引入到随后注射肿瘤的相同部位时,注射同种异体IL-2的成纤维细胞注射可以有效地预防脑肿瘤的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号